《大行報告》美銀證券下調百濟神州(06160.HK)目標價至123.32元 評級「中性」
美銀證券發表報告指,百濟神州(06160.HK)料下半年推出自主小分子抑制劑澤布替尼(BRUKINSA)的臨床數據,同時料替雷利珠單抗(Tislelizumab)將獲得批准。該行表示,公司正構建以替雷利珠單抗為中心的泛腫瘤I-O渠道,並加速重點研究腫瘤類型,以及擴張其產品組合至致癌信號傳導標靶療法和腫瘤相關抗原療法。該行將其H股目標價由136.22元下調至123.32元,維持其評級為「中性」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.